<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://repozitorij.uni-lj.si/IzpisGradiva.php?id=185257"><dc:title>Identification and prioritisation of tumour antigen candidates from 79 glioblastoma transcriptomes</dc:title><dc:creator>Kert,	Špela	(Avtor)
	</dc:creator><dc:creator>Pižem,	Jože	(Avtor)
	</dc:creator><dc:creator>Petrin,	Sara	(Avtor)
	</dc:creator><dc:creator>Bošnjak,	Matic	(Avtor)
	</dc:creator><dc:creator>Jerala,	Miha	(Avtor)
	</dc:creator><dc:creator>Matjašič,	Alenka	(Avtor)
	</dc:creator><dc:creator>Zupan,	Andrej	(Avtor)
	</dc:creator><dc:subject>computational immunology</dc:subject><dc:subject>glioblastoma</dc:subject><dc:subject>HLA class I</dc:subject><dc:subject>transcriptome sequencing</dc:subject><dc:subject>tumor antigens</dc:subject><dc:description>Glioblastoma (GBM) is an aggressive brain tumour with limited responsiveness to current immunotherapeutic approaches, partly due to its low mutational burden and intra-tumour heterogeneity. A systematic understanding of the tumour antigen landscape is therefore essential for advancing tumour immunology and supporting rational development of immunotherapeutic strategies. In this study, we performed whole-transcriptome sequencing of RNA extracted from 79 formalin-fixed paraffin-embedded (FFPE) IDH-wildtype GBM samples to systematically identify and prioritise candidate tumour antigens derived from three sources: single-nucleotide variants (SNVs), overexpressed tumour-associated antigens (TAAs), and gene fusion events. Candidate peptides were evaluated using integrated computational criteria, including transcript expression, predicted antigen processing features, peptide-HLA binding affinity and stability. Across the cohort, mutation-derived tumor-specific antigens (TSAs) were largely private to individual samples, whereas TAAs constituted a larger and more recurrent candidate pool. Despite comparable predicted binding characteristics across antigen classes, recurrence patterns differed substantially, reflecting their distinct biological origins. Fusion-derived candidates were rare and sample-specific. Predicted peptide presentation was disproportionately associated with a limited subset of HLA class I alleles. Collectively, this study provides a systematically prioritized catalogue of transcriptionally expressed GBM antigen candidates and offers a comparative evaluation of mutation-, expression-, and fusion-derived antigen sources within a unified transcriptome-based framework.</dc:description><dc:date>2026</dc:date><dc:date>2026-07-30 08:36:35</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>185257</dc:identifier><dc:language>sl</dc:language></rdf:Description></rdf:RDF>
